...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of biological sciences >Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors
【24h】

Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors

机译：三阴性乳腺癌中乳腺癌干细胞和瘤内异质性的预后评价

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Triple-negative breast cancer (TNBC) is a tumor subtype with aggressive behavior and poor clinical outcome for lacking effective therapies. Breast cancer stem cells (BCSCs) have been suggested to have tumor-initiating properties, but it remains unclear whether their presence contributes to the increased aggressiveness and poor prognosis of TNBC. Also, the breast cancers display frequent inter- and intra-tumor heterogeneity, which adds the complexity in diagnosis and predicting prognosis. Here we investigated the clinical relevance and prognostic value of the BCSC markers, CD44+/CD24-, aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and CD133 in 88 TNBC cases. We found that a few patients displayed spatial heterogeneity of the BCSC markers in expression, which was defined as intratumor stemness heterogeneity (ITSH) below. There was no significant correlation between any BCSC marker alone or ITSH and progression-free survival (PFS). Interestingly, the combined BCSC phenotype by CD44+/CD24- and ALDH1A1 was significantly associated with worse PFS ( P = 0.009). Further stratification analysis revealed that this combined BCSC phenotype was an independent prognostic factor for PFS in some subgroups. In conclusion, we demonstrated the existence of ITSH in TNBC and found that the ITSH as well as a single BCSC marker was not significantly associated with survival, whereas combing the analysis of BCSC markers could improve prognostic value. Our findings may lead to an improvement of prognostic indicators in TNBC.
机译：三阴性乳腺癌（TNBC）是一种肿瘤亚型，由于缺乏有效的治疗方法，具有攻击性且临床效果差。乳腺癌干细胞（BCSCs）已被认为具有启动肿瘤的特性，但尚不清楚它们的存在是否有助于TNBC的侵袭性增加和预后不良。而且，乳腺癌表现出频繁的肿瘤内和肿瘤内异质性，这增加了诊断和预测预后的复杂性。在这里，我们调查了88例TNBC患者中BCSC标记CD44 + / CD24 -，醛脱氢酶家族1成员A1（ALDH1A1）和CD133的临床相关性和预后价值。我们发现一些患者在表达中显示了BCSC标记的空间异质性，以下定义为肿瘤内干异质性（ITSH）。没有任何单独的BCSC标记或ITSH与无进展生存期（PFS）之间没有显着相关性。有趣的是，CD44 + / CD24 -和ALDH1A1联合的BCSC表型与较差的PFS显着相关（P = 0.009）。进一步的分层分析表明，在某些亚组中，这种合并的BCSC表型是PFS的独立预后因素。总之，我们证明了TNBC中ITSH的存在，并发现ITSH和单个BCSC标记与生存率没有显着相关，而结合BCSC标记的分析可以提高预后价值。我们的发现可能会导致TNBC的预后指标改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号